Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
September 27, 2011

OncoSec ElectroChemotherapy shows efficacy against cancer

OncoSec Medical has presented positive results a Phase IV head and neck cancer trial, which has demonstrated that OMS ElectroChemotherapy is safe and well-tolerated.

OncoSec Medical has presented positive results a Phase IV head and neck cancer trial, which has demonstrated that OMS ElectroChemotherapy is safe and well-tolerated.

Patient survival following treatment at eight months was 95% and 86% at 24 months.

Preliminary analysis of the data demonstrates that the primary endpoint, local control of the tumour at eight months, was achieved.

The majority of adverse events were pain, infection, edema and dysphagia.

Principal investigator Lennart Lofgrenand said that this simple and novel delivery of bleomycin, an approved chemotherapeutic agent, through reversible electroporation, has shown a marked improvement in potency while delivering a much lower and safer concentration of the drug.

OncoSec Medical president and CEO Punit Dhillon said the data supports the uniqueness of OMS ElectroChemotherapy in its ability to achieve selective destruction of cancerous tumours while sparing healthy normal tissue including highly vascularised and innervated surrounding structures, providing physicians with a flexible treatment alternative.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
The powerful networks advancing life sciences in Charleston | USA
The power of infrastructure: How Charleston | SC | USA is expanding horizons for life science companies

The company also reported results from a Phase I study of 13 patients with recurrent breast cancer treated with OMS ElectroChemotherapy, which demonstrated that the therapy was safe, well-tolerated and achieved a 75% complete tumour response rate.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Get important industry news and analysis sent to your inbox
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU